Anti-interleukin-6 (tocilizumab) therapy in Takayasu's arteritis: a real life experience
TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.50, sa.1, ss.31-36, 2020 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 50 Sayı: 1
- Basım Tarihi: 2020
- Doi Numarası: 10.3906/sag-1906-39
- Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.31-36
- Anahtar Kelimeler: Anti-interleukin-6, tocilizumab, Takayasu's arteritis, GIANT-CELL ARTERITIS, DISEASE-ACTIVITY, CASE SERIES, EFFICACY, RESISTANT, SAFETY
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Hacettepe Üniversitesi Adresli: Evet
Özet
Background/aim: Tumour necrosis factor inhibitors and anti-interleukin-6 (anti-IL-6) therapies are increasingly being used in Takayasu's arteritis (TA) patients who are unresponsive to corticosteroids +/- conventional immunosuppressive agents. The aim of this study is to assess the efficacy and safety of anti-IL-6 (tocilizumab) therapy in refractory TA patients in real life.